HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
KTE-X19
This study is now recruiting.
Patients with no available curative treatment options with leukemia are eligible to participate in this study to test an experimental approach called gene transfer that involves B cells. This study will take the patients white blood cells - T cells - and change them to turn against the cancer.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at motleyl [at] chop.edu or 267-426-6857.
Eligibility & Criteria
IRB #:
16-013488
Official Title:
A Phase 1/2 Multi-center Study Evaluating The Safety And Efficacy Of Kte-x19 In Pediatric And Adolescent Subjects With Relapsed/refractory B-precursor Acute Lymphoblastic Leukemia Or Relapsed/refractory B Cell Non Hodgkin Lymphoma (Zuma-4)
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 - 21 Years
Gender:
All
Leader
